Inherited genetic predisposition in breast cancer: A population-based perspective

Cancer

Volumn 86, Issue 8 SUPPL., 1999, Pages 1673-1681

  Rebbeck, Timothy R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Inherited susceptibility; Major gene; Polygene

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CONFERENCE PAPER; GENETIC EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; ONCOGENE; PEDIGREE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033569803     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19991015)86:8+<1673::aid-cncr6>3.0.co;2-b     Document Type: Conference Paper

References (58)

1. Lilienfeld AM, Lilienfeld DE. Foundations of epidemiology. New York: Oxford University Press, 1980:346-7.
2. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993;52:678-701
3. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-21
4. Foulkes WD. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM 1995;88:853-63.
5. Redston M, Nathanson KC, Yuan ZQ, Neuhausen SL, Satagopan J, Wong N, et al. The APCI1307K polymorphism and breast cancer risk. Nat Genet. 1998;20:13-4.
6. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press, 1993.
7. Ott J. Analysis of human genetic linkage. Baltimore: Johns Hopkins University Press, 1991.
8. Anderson DE. Genetic study of breast cancer: identification of a high risk group. Cancer 1974;34:1090-7.
9. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 1991;48:232-42.
10. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1989;250:1684-9.
11. Miki Y, Swensen J, Shattuck-Eidens S, Futreal A, Harshman K, Tavigian S, et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA 1. Science 1994; 266:66-71.
12. Lindor NM, Greene MH, and the Mayo Familial Cancer Program. Concise handbook of family cancer syndromes. J Natl Cancer Inst 1998;90:1039-71.
13. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in BC families. The BC Linkage Consortium. Am J Hum Genet 1998;62:676-89.
14. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-9.
15. Rebbeck TR, Blackwood MA, Walker AH, White DL, Godwin AK, Daly MB, et al. Association of breast cancer incidence with NAT2 genotype and smoking in BRCA1 variant carriers. Am J Hum Genet 1998;61:A46.
16. Grade K, Hoffken K, Kath R, Nothnagel A, Bender E, Scherneck S. BRCA1 variants and phenotype. J Cancer Res Clin Oncol 1997;123:69-70.
17. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline variants of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995;11:428-33.
18. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline variants of the BRCA2 gene. Nat Genet 1997;15:103-5.
19. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeats (VNTR) locus. Nat Genet 1996;12:309-11.
20. Rebbeck TR, Kantoff PW, Krithivas K, Narod SA, Godwin AK, Daly MB, et al. Modification of breast cancer risk in BRCA1 variant carriers by the androgen receptor CAG repeat polymorphism. Am J Hum Genet 1999;64:1371-7.
21. Narod SA, Goldgar D, Cannon-Albright L, Weber BL, Moslehi R, Ives E, et al. Risk modifiers in carriers of BRCA1 variants. Int J Cancer 1995;64:394-8.
22. Ursin G, Henderson BE, Haue RW, Pike MC, Zhou N, Diep A, et al. Does oral contraceptive use increase the risk of BC in women with BRCA1/BRCA2 variants more than in other women? Cancer Res 1991;57:3678-81.
23. McMahon B, Trichopolous D, Cole P, Brown J. Cigarette smoking and urinary estrogens. N Engl J Med 1986;307: 1062-8.
24. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin P, et al. The effect of smoking on BC in BRCA1 and BRCA2 carriers. J Natl Cancer Inst 1998;90:761-6.
25. Schulte P, Perera F. Molecular epidemiology: principles and practices. San Diego: Academic Press, 1993.
26. Begg CB, Zhang ZF. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 1994;3:173-5.
27. Piegorsch WW, Weinberg CR, Taylor JA. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 1994;13:153-62.
28. Rubinstein P, Walker M, Carpenter C, Carrier C, Krassner J, Falk C, et al. Genetics of HLA disease associations: the use of the haplotype relative risk (HRR) and the "haplo-delta" (Dh) estimates in juvenile diabetes from three racial groups. Hum Immunol 1981;3:384-8.
29. Spielman RS, McGinnis RE, Ewens WJ. Transmission disequilibrium test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506-16.
30. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of BC. Carcinogenesis 1997;18:2127-32.
31. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and BC risk. JAMA 1996; 276:1494-501.
32. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Medicine 1987;316:1289-94.
33. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, et al. Heterozygous ATM variants do not contribute to early onset of BC. Nat Genet 1997;15:307-10.
34. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial BC. Cancer Res 1998;58:1376-9.
35. Vorechovsky I, Rasio D, Luo L, Monaco C, Hammarstrom L, Webster AD, et al. The ATM gene and susceptibility to BC: analysis of 38 breast tumors reveals no evidence for variant. Cancer Res 1996;56:2726-32.
36. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997;277:915-9.
37. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific variants of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
38. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 variants in a familial syndrome of BC, sarcomas, and other neoplasms. Science 1990;250:1233-8.
39. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
40. Birch JM, Hartley AL, Ticker KJ. Prevalence and diversity of constitutional variants in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-1304.
41. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: a cutaneous marker of BC. Cancer 1978 41:2393-8.
42. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
43. Honchel R, Hailing KC, Schaid DJ, Pittelkow M, Thibodeau SN. Microsatellite instability in Muir-Torre syndrome. Cancer Res 1994;54:1159-63.
44. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by variants in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
45. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC, Speizer FE, et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms, and BC risk in the Nurses' Health Study. Cancer Res 1998;58:667-71
46. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Pari FF. BC and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58:65-70.
47. Jennings M, Sweetand H, Smith CAD, Wolf CR, Lennard MS, Tucker GT, et al. Lack of a relationship between the debrisoquine (CYP2D6) and mephenytoin (CYP2C19) oxidation polymorphisms and susceptibility to breast cancer. Breast 1996;5:254-8.
48. Ladona MG, Abildua RE, Ladero JM, Roman JM, Plaza MA, Agundez JAG, et al. CYP2D6 genotypes in Spanish women with BC. Cancer Lett 1996;99:23-8.
49. Shields PG, Ambrosone CB, Graham S, Bowman ED, Harrington AM, Gillenwater KA, et al. A cytochrome P4502E1 genetic polymorphism and tobacco smoking in BC. Mol Carcinog 1996;17:144-50.
50. Helzlsouer KJ, Selmin O, Huang HY. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of BC. J Natl Cancer Inst 1998;90: 512-8.
51. Maugard CM, Charrier J, Bignon YJ. Allelic deletion at glutathione S-transferase M1 focus and its association with BC susceptibility. Chem Biol Interact 1998;112:365-75.
52. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and variants in the HRAS1 minisatellite locus. N Engl J Med 1993;329:517-23.
53. Agundez JA, Ladero JM, Olivera M, Abildua R, Roman JM, Benitez J. Genetic analysis of the arylamine N-acetyltransferase polymorphism in BC patients. Oncology 1995;52:7-11.
54. Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen SL, Blackwood MA, Godwin AK, et al. Modification of breast cancer risk in BRCA1 mutation carriers by the AIB1 gene. Proc Amer Assoc Cancer Res 1999;40:1293.
55. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. New Engl Journ Med 1998;339:424-8.
56. Thompson PA, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, et al. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res 1998;58:2107-10.
57. Lavigne JA, Helzlsouer KJ, Huang HY, Strickland PT, Bell DA, Selmin O, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. 1997;57:5493-7.
58. Millikan RC, Pittman GS, Tse CK, Duell E, Newman B, Savitz D, et al. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis 1998;19:1943-7.